- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03611582
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program (STEP 3)
November 10, 2021 updated by: Novo Nordisk A/S
Effect and Safety of Semaglutide 2.4 mg Once-weekly as Adjunct to Intensive Behavioural Therapy in Subjects With Overweight or Obesity
This study will look at the change in participant's body weight from the start to the end of the study.
This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine.
Together with the medicine, the participant will also be part of an intensive lifestyle program where the participant will have talks with study staff about healthy food choices, what the participant can do to lose weight and be more physically active.
The participant will either get semaglutide or "dummy" medicine - which treatment the participant gets is decided by chance.
The participant will need to take 1 injection once a week.
The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm.
For the first 2 months the participant will be on a low calorie diet.
The diet is made up of bars, shakes and 1 low calorie pre-prepared meal for each day.
The study will last for about 1.5 years.
The participant will have 32 clinic visits with the study doctor.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
611
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Novo Nordisk Investigational Site
-
Montgomery, Alabama, United States, 36106
- Novo Nordisk Investigational Site
-
-
Arizona
-
Peoria, Arizona, United States, 85381
- Novo Nordisk Investigational Site
-
-
California
-
Anaheim, California, United States, 92801
- Novo Nordisk Investigational Site
-
Escondido, California, United States, 92025
- Novo Nordisk Investigational Site
-
Fresno, California, United States, 93720
- Novo Nordisk Investigational Site
-
Fullerton, California, United States, 92835
- Novo Nordisk Investigational Site
-
Huntington Beach, California, United States, 92648
- Novo Nordisk Investigational Site
-
Los Angeles, California, United States, 90057
- Novo Nordisk Investigational Site
-
Walnut Creek, California, United States, 94598
- Novo Nordisk Investigational Site
-
-
Colorado
-
Golden, Colorado, United States, 80401
- Novo Nordisk Investigational Site
-
-
Florida
-
Kissimmee, Florida, United States, 34744
- Novo Nordisk Investigational Site
-
Panama City, Florida, United States, 32401
- Novo Nordisk Investigational Site
-
Plantation, Florida, United States, 33324
- Novo Nordisk Investigational Site
-
-
Georgia
-
Roswell, Georgia, United States, 30076
- Novo Nordisk Investigational Site
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96814
- Novo Nordisk Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60607
- Novo Nordisk Investigational Site
-
Evanston, Illinois, United States, 60201-2477
- Novo Nordisk Investigational Site
-
Skokie, Illinois, United States, 60077
- Novo Nordisk Investigational Site
-
-
New York
-
Albany, New York, United States, 12203
- Novo Nordisk Investigational Site
-
Endwell, New York, United States, 13760
- Novo Nordisk Investigational Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27517
- Novo Nordisk Investigational Site
-
Greensboro, North Carolina, United States, 27408
- Novo Nordisk Investigational Site
-
Hickory, North Carolina, United States, 28601
- Novo Nordisk Investigational Site
-
Raleigh, North Carolina, United States, 27609
- Novo Nordisk Investigational Site
-
Wilmington, North Carolina, United States, 28401
- Novo Nordisk Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-3317
- Novo Nordisk Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Novo Nordisk Investigational Site
-
Mount Pleasant, South Carolina, United States, 29464
- Novo Nordisk Investigational Site
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37912
- Novo Nordisk Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78731
- Novo Nordisk Investigational Site
-
Dallas, Texas, United States, 75230
- Novo Nordisk Investigational Site
-
Dallas, Texas, United States, 75226
- Novo Nordisk Investigational Site
-
Dallas, Texas, United States, 75231
- Novo Nordisk Investigational Site
-
Rockwall, Texas, United States, 75032
- Novo Nordisk Investigational Site
-
Round Rock, Texas, United States, 78681
- Novo Nordisk Investigational Site
-
-
Utah
-
Saint George, Utah, United States, 84790
- Novo Nordisk Investigational Site
-
-
Virginia
-
Arlington, Virginia, United States, 22206
- Novo Nordisk Investigational Site
-
Newport News, Virginia, United States, 23606
- Novo Nordisk Investigational Site
-
Winchester, Virginia, United States, 22601-3834
- Novo Nordisk Investigational Site
-
-
Washington
-
Olympia, Washington, United States, 98502
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female, age more than or equal to 18 years at the time of signing informed consent
- Body mass index more than or equal to 30 kg/m^2 or more than or equal to 27 kg/m^2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease
- History of at least one self-reported unsuccessful dietary effort to lose body weight
Exclusion Criteria:
- Hemoglobin A1c more than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory at screening
- A self-reported change in body weight more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Semaglutide
Participants will receive semaglutide 2.4 mg during 68-week treatment period in addition to intensive behavioural therapy.
|
Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week).
The dose will be escalated to next level every 4 weeks.
|
Placebo Comparator: Semaglutide placebo
Participants will receive semaglutide placebo during 68-week treatment period in addition to intensive behavioural therapy.
|
S.c.
injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week).
The dose will be escalated to next level every 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Body Weight (%)
Time Frame: Baseline (week 0) to week 68
|
Change in body weight from baseline (week 0) to week 68 is presented.
The endpoint was evaluated based on the data from both in-trial and on-treatment periods.
In-trial observation period: the uninterrupted time interval from the start of randomisation (week 0) to last trial-related subject-site contact (week 75).
On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 2 weeks of follow-up.
It excludes any period of temporary treatment interruption.
Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).
|
Baseline (week 0) to week 68
|
Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 5%
Time Frame: After 68 weeks
|
Number of participants who achieved greater than or equal to (≥) 5% weight loss after 68 weeks is presented.
In the reported data, 'Yes' infers the number of participants who have achieved ≥ 5% weight loss, whereas 'No' infers the number of participants who have not achieved ≥ 5% weight loss.
The endpoint was evaluated based on the data from both in-trial and on-treatment observation periods.
In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).
On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 2 weeks of follow-up.
It excludes any period of temporary treatment interruption.
|
After 68 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 10%
Time Frame: After 68 weeks
|
Number of participants who achieved greater than or equal to (≥) 10% weight loss after 68 weeks is presented.
In the reported data, 'Yes' infers number of participants who have achieved ≥ 10% weight loss whereas 'No' infers number of participants who have not achieved ≥ 10% weight loss.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).
|
After 68 weeks
|
Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 15%
Time Frame: After 68 weeks
|
Number of participants who achieved greater than or equal to (≥) 15% weight loss after 68 weeks is presented.
In the reported data, 'Yes' infers number of participants who have achieved ≥ 15% weight loss whereas 'No' infers number of participants who have not achieved ≥ 15% weight loss.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).
|
After 68 weeks
|
Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 20%
Time Frame: After 68 weeks
|
Number of participants who achieved greater than or equal to (≥) 20% weight loss after 68 weeks is presented.
In the reported data, 'Yes' infers number of participants who have achieved ≥ 20% weight loss whereas 'No' infers number of participants who have not achieved ≥ 20% weight loss.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomization (week 0) to last trial-related subject-site contact (week 75).
|
After 68 weeks
|
Change in Waist Circumference
Time Frame: Baseline (week 0) to week 68
|
Change in waist circumference from baseline (week 0) to week 68 is presented.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in Systolic Blood Pressure
Time Frame: Baseline (week 0) to week 68
|
Change in systolic blood pressure from baseline (week 0) to week 68 is presented.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in Short Form-36 (SF-36) - Physical Functioning Score
Time Frame: Baseline (week 0) to week 68
|
SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL).
SF-36v2™ questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary and mental component summary).
The 0-100 scale scores from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population.
In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively.
Change from week 0 in the domain scores and component summary scores were evaluated at week 68.
A positive change score indicates an improvement since baseline.
These endpoints were evaluated based on the data from in-trial observation period which is the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in Body Weight (Kg)
Time Frame: Baseline (week 0) to week 68
|
Change in body weight from baseline (week 0) to week 68 is presented.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in Body Mass Index
Time Frame: Baseline (week 0) to week 68
|
Change in body mass index from baseline (week 0) to week 68 is presented.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in HbA1c (%)
Time Frame: Baseline (week 0) to week 68
|
Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 68 is presented.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in HbA1c (mmol/Mol)
Time Frame: Baseline (week 0) to week 68
|
Change in HbA1c from baseline (week 0) to week 68 is presented.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in Fasting Plasma Glucose
Time Frame: Baseline (week 0) to week 68
|
Change in fasting plasma glucose from week 0 to week 68 is presented.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in Fasting Serum Insulin
Time Frame: Baseline (week 0) to week 68
|
Change in fasting serum insulin from week 0 to week 68 [measured as milli-international units per milliliter (mIU/mL)] is presented as ratio to baseline.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in Diastolic Blood Pressure
Time Frame: Baseline (week 0) to week 68
|
Change in diastolic blood pressure from baseline (week 0) to week 68 is presented.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in Total Cholesterol
Time Frame: Baseline (week 0) to week 68
|
Change in fasting total cholesterol from baseline (week 0) to week 68 (measured as mg/dL) is presented as ratio to baseline.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in High-density Lipoproteins (HDL)
Time Frame: Baseline (week 0) to week 68
|
Change in fasting HDL from baseline (week 0) to week 68 (measured as mg/dL) is presented as ratio to baseline.The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in Low-density Lipoproteins (LDL)
Time Frame: Baseline (week 0) to week 68
|
Change in fasting LDL from baseline (week 0) to week 68 (measured as mg/dL) is presented as ratio to baseline.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in Very Low Density Lipoprotein (VLDL)
Time Frame: Baseline (week 0) to week 68
|
Change in fasting VLDL from baseline (week 0) to week 68 (measured as mg/dL) is presented as ratio to baseline.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in Free Fatty Acids
Time Frame: Baseline (week 0) to week 68
|
Change in fasting free fatty acids from baseline (week 0) to week 68 (measured as mg/dL) is presented as ratio to baseline.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in Triglycerides
Time Frame: Baseline (week 0) to week 68
|
Change in fasting triglycerides from baseline (week 0) to week 68 (measured as mg/dL) is presented as ratio to baseline.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in High Sensitivity C-reactive Protein
Time Frame: Baseline (week 0) to week 68
|
Change in high sensitivity C-reactive protein from baseline (week 0) to week 68 is presented.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Change in Plasminogen Activator Inhibitor-1 Activity
Time Frame: Baseline (week 0) to week 68
|
Change in plasminogen activator inhibitor-1 activity from baseline (week 0) to week 68 is presented.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 68
|
Participants Who Achieve (Yes/no): Responder Definition Value for SF-36 Physical Functioning Score
Time Frame: After 68 weeks
|
The observed number of participants experiencing a meaningful within participant improvement in SF-36 Physical function after 68 weeks was determined based on two thresholds.
The threshold of 4.3 is the default generic responder threshold defined in SF-36 manual for a general population.
The threshold of 3.7 is specific for overweight or obese population included in the study and calculated using patient global rating anchor questionnaires to reflect participants' own perspective based on Food and Drug Administration (FDA) recommendations.
In the reported data, "Yes" infers number of participants who have achieved an improvement in score greater than or equal to the threshold and "No" infers number of participants who have not achieved an improvement in score greater than or equal to the threshold.
The endpoint was evaluated based on the in-trial observation period which is uninterrupted time interval from randomization (week 0) to last trial related subject-site contact (week 75).
|
After 68 weeks
|
Change in Body Weight
Time Frame: Baseline (week 0) to week 8
|
Change in body weight from baseline (week 0) to week 8 is presented.
The endpoint was evaluated based on the data from in-trial observation period.
In-trial observation period: the uninterrupted time interval from start of randomisation (week 0) to last trial-related subject-site contact (week 75).
|
Baseline (week 0) to week 8
|
Number of Treatment-emergent Adverse Events (AEs)
Time Frame: Baseline (week 0) to week 75
|
An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product.
All AEs mentioned here are treatment emergent adverse events (TEAE) defined as an event that had onset date (or increase in severity) on or after the first day of exposure to treatment.
The endpoint was evaluated based on the data from on-treatment observation period.
On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 7 weeks of follow-up.
It excludes any period of temporary treatment interruption.
Temporary treatment interruption is defined as more than 7 consecutive missed doses (off-treatment period).
|
Baseline (week 0) to week 75
|
Number of Serious Adverse Events (SAEs)
Time Frame: Baseline (week 0) to week 75
|
A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage.
The SAEs occurred from week 0 to week 75 is presented.
The endpoint was evaluated based on the data from on-treatment observation period.
On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68), including 7 weeks of follow-up.
It excludes any period of temporary treatment interruption.
Temporary treatment interruption is defined as more than 7 consecutive missed doses (off-treatment period).
|
Baseline (week 0) to week 75
|
Change in Pulse
Time Frame: Baseline (week 0) to week 68
|
Change in pulse from baseline (week 0) to week 68 is presented.
The endpoint was evaluated based on the data from on-treatment observation period.
On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up.
It excludes any period of temporary treatment interruption.
Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).
|
Baseline (week 0) to week 68
|
Change in Amylase
Time Frame: Baseline (week 0) to week 68
|
Change in amylase (measured as U/L) is presented as ratio to baseline.
The endpoint was evaluated based on the data from on-treatment observation period.
On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up.
It excludes any period of temporary treatment interruption.
Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).
|
Baseline (week 0) to week 68
|
Change in Lipase
Time Frame: Baseline (week 0) to week 68
|
Change in lipase (measured as U/L) is presented as ratio to baseline.
The endpoint was evaluated based on the data from on-treatment observation period.
On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up.
It excludes any period of temporary treatment interruption.
Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).
|
Baseline (week 0) to week 68
|
Change in Calcitonin
Time Frame: Baseline (week 0) to week 68
|
Change in calcitonin (measured as ng/L) is presented as ratio to baseline.
The endpoint was evaluated based on the data from on-treatment observation period.
On-treatment observation period: includes all time intervals in which participants are considered to be on treatment from the first (week 0) to last trial product administration (week 68) including 2 weeks of follow-up.
It excludes any period of temporary treatment interruption.
Temporary treatment interruption is defined as more than 2 consecutive missed doses (off-treatment period).
|
Baseline (week 0) to week 68
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, Lingvay I, Thomsen M, Wadden TA, Wharton S, Wilding JPH, Rubino D. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring). 2020 Jun;28(6):1050-1061. doi: 10.1002/oby.22794.
- Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831.
- Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, Machineni S, Varbo A, Wilding JPH, Wallenstein SOR, le Roux CW. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care. 2022 Oct 1;45(10):2396-2405. doi: 10.2337/dc21-1785.
- O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018 Aug 25;392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2. Epub 2018 Aug 16.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2018
Primary Completion (Actual)
March 18, 2020
Study Completion (Actual)
April 28, 2020
Study Registration Dates
First Submitted
July 17, 2018
First Submitted That Met QC Criteria
August 1, 2018
First Posted (Actual)
August 2, 2018
Study Record Updates
Last Update Posted (Actual)
November 11, 2021
Last Update Submitted That Met QC Criteria
November 10, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN9536-4375
- U1111-1200-8199 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Semaglutide
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
-
Novo Nordisk A/SCompletedObesityUnited States, Israel, United Kingdom, Denmark, Germany, Netherlands, Canada, Argentina, Czechia, Hungary, Poland, Spain, Australia
-
Novo Nordisk A/SCompletedObesity | Diabetes Mellitus, Type 2 | OverweightKorea, Republic of, Hong Kong, Brazil, China
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Novo Nordisk A/SCompletedType 2 Diabetes | Healthy VolunteersUnited States, Canada
-
Sansum Diabetes Research InstituteNovo Nordisk A/STerminatedDiabetes Mellitus, Type 2 | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, Italy, Spain, Canada, Hungary
-
Novo Nordisk A/SCompletedObesity | OverweightJapan, Korea, Republic of
-
Novo Nordisk A/SCompletedOverweight or Obesity | Metabolism and Nutrition DisorderUnited States, India, Mexico, Russian Federation, United Kingdom, Canada, Denmark, Finland, Belgium, Japan, Taiwan, France, Poland, Germany, Bulgaria, Argentina, Puerto Rico
-
Novo Nordisk A/SRecruiting